Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study  Prof Rosangela Invernizzi, MD, Federica Quaglia, MD, Catherine Klersy, MD, Fabio Pagella, MD, Federica Ornati, PhD, Francesco Chu, MD, Elina Matti, MD, Giuseppe Spinozzi, BME, Sara Plumitallo, MS, Pierangela Grignani, PhD, Carla Olivieri, PhD, Raffaella Bastia, AS, Francesca Bellistri, MD, Prof Cesare Danesino, MD, Prof Marco Benazzo, MD, Prof Carlo L Balduini, MD  The Lancet Haematology  Volume 2, Issue 11, Pages e465-e473 (November 2015) DOI: 10.1016/S2352-3026(15)00195-7 Copyright © 2015 Elsevier Ltd Terms and Conditions

Figure 1 Change in patient epistaxis parameters with time Epistaxis parameters are frequency (A), intensity (B), and duration (C). The Lancet Haematology 2015 2, e465-e473DOI: (10.1016/S2352-3026(15)00195-7) Copyright © 2015 Elsevier Ltd Terms and Conditions

Figure 2 Haemoglobin concentrations (A) and transfusion need (B) with time Values are means of all patients at each timepoint (95% CI). The Lancet Haematology 2015 2, e465-e473DOI: (10.1016/S2352-3026(15)00195-7) Copyright © 2015 Elsevier Ltd Terms and Conditions

Figure 3 Relapse-free survival after end of treatment One patient was censored from the analysis, because they relapsed before the end of treatment. The Lancet Haematology 2015 2, e465-e473DOI: (10.1016/S2352-3026(15)00195-7) Copyright © 2015 Elsevier Ltd Terms and Conditions